Journal of diabetes science and technology
-
J Diabetes Sci Technol · May 2011
Monitoring of glucose in brain, adipose tissue, and peripheral blood in patients with traumatic brain injury: a microdialysis study.
Episodes of hyperglycemia are considered to be a secondary insult in traumatically brain-injured patients and have been shown to be associated with impaired outcome. Intensive insulin therapy to maintain a strict glucose level has been suggested to decrease morbidity and mortality in critically ill patients but this aggressive insulin treatment has been challenged. One aspect of strict glucose control is the risk of developing hypoglycemia. Extracellular intracerebral hypoglycemia monitored by intracerebral microdialysis has been shown to correlate with poor outcome. Monitoring of blood glucose during neurointensive care is important because adequate glucose supply from the systemic circulation is crucial to maintain the brain's glucose demand after brain injury. This study investigates the correlation of glucose levels in peripheral blood, subcutaneous (SC) fat, and extracellular intracerebral tissue in patients with severe traumatic brain injury during neurointensive care. ⋯ This study indicates that there is a good correlation between blood glucose and adipose tissue during initial and later time points in the neurointensive care unit whereas the correlation between blood and brain seems to be more individualized among patients. This emphasizes the importance of using intracerebral microdialysis to ensure adequate intracerebral levels of glucose in patients suffering from severe traumatic brain injury and to detect hypoglycemia in the brain despite normal levels of blood glucose.
-
J Diabetes Sci Technol · May 2011
Review Meta AnalysisIntensive insulin therapy in critically ill hospitalized patients: making it safe and effective.
Intensive insulin therapy (IIT) for hyperglycemia in critically ill patients has become a standard practice. Target levels for glycemia have fluctuated since 2000, as evidence initially indicated that tight glycemic control to so-called normoglycemia (80-110 mg/dl) leads to the lowest morbidity and mortality without hypoglycemic complications. Subsequent studies have demonstrated minimal clinical benefit combined with greater hypoglycemic morbidity and mortality with tight glycemic control in this population. ⋯ Three questions must be answered to understand the role of IIT for defined populations of critically ill patients: (1) How safe is IIT, with various glycemic targets, from the risk of hypoglycemia? (2) How tightly must BG be controlled for this approach to be effective? (3) What role does the accuracy of BG measurements play in affecting the safety of this method? For each state of impaired glucose regulation seen in the hospital, such as hyperglycemia, hypoglycemia, or glucose variability, the benefits, risks, and goals of treatment, including IIT, might differ. With improved accuracy of BG monitors, IIT might be rendered even more intensive than at present, because patients will be less likely to receive inadvertent overdosages of insulin. Greater doses of insulin, but with dosing based on more accurate glucose levels, might result in less hypoglycemia, less hyperglycemia, and less glycemic variability.